SCHEMBL738119

SCHEMBL738119

NC(=O)c1cnc(NCCc2ccc(O)cc2)nc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 5/20 0.57
HDAC3 O15379 4/20 0.56
HDAC1 Q13547 4/20 0.56
HDAC2 Q92769 4/20 0.56
HDAC6 Q9UBN7 3/20 0.56
VNN1 O95497 6/20 0.49
HDAC8 Q9BY41 1/20 0.47
KDM4E B2RXH2 1/20 0.44
F13A1 P00488 1/20 0.44
RAB9A P51151 1/20 0.44
ULK1 O75385 1/20 0.44
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
TTBK1 Q5TCY1 1/20 0.43
TTBK2 Q6IQ55 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4575737 0.77 TMEM97 (0.49) STAT6HDAC3HDAC1HDAC2HDAC6
SCHEMBL29637090 0.74 RAB9A (0.50) STAT6HDAC3HDAC1HDAC2HDAC6
SCHEMBL31141609 0.74 HDAC3 (0.60) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL31141710 0.74 HDAC3 (0.80) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL31141641 0.74 HDAC3 (0.60) HDAC3HDAC1HDAC2HDAC6HDAC8
SCHEMBL31141667 0.74 HDAC3 (0.64) HDAC3HDAC1HDAC2HDAC6HDAC8
SCHEMBL2384951 0.74 STAT6 (0.60) STAT6ULK1
SCHEMBL31141722 0.73 HDAC3 (0.79) STAT6HDAC3HDAC1HDAC2HDAC6
SCHEMBL4730507 0.71 HDAC3 (1.00) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL31141715 0.71 HDAC3 (0.63) HDAC3HDAC1HDAC2HDAC6VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188457-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMA BY INHIBITION OF THE TFPI2-CD51-STAT6 SIGNALING AXIS NORTHWESTERN UNIVERSITY 2025-06-12 US disclosed
US-11414410-B2 Inhibitors of protein kinases ALEXION PHARMACEUTICALS, INC. (US) 2022-08-16 US disclosed
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-10385080-B2 STAT6 inhibitors BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-08-20 US disclosed
US-20180222931-A1 STAT6 INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-08-09 US disclosed
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2018-07-05 US disclosed
US-9868729-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2018-01-16 US disclosed
US-9765099-B2 STAT6 inhibitors BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-09-19 US disclosed
EP-2321283-B1 2,6-DIAMINO-PYRIMIDIN-5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARM INC (US) 2016-07-13 EP disclosed
US-20160145279-A1 STAT6 INHIBITORS BAYLOR COLLEGE OF MEDICINE (US) 2016-05-26 US disclosed
EP-2323993-B1 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARM INC (US) 2015-06-03 EP disclosed
US-20150094298-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-04-02 US disclosed
US-8937070-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-01-20 US disclosed
US-20140031361-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2014-01-30 US disclosed
US-8501944-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385080-B2 STAT6 inhibitors STAT6, STAT3, STAT1 STAT6 1/4885HDAC3 131/4885HDAC1 164/4885
US-20160145279-A1 STAT6 INHIBITORS STAT6, STAT3, STAT1 STAT6 1/4885HDAC3 131/4885HDAC1 164/4885
US-20180222931-A1 STAT6 INHIBITORS STAT6, STAT3, STAT1 STAT6 1/4885HDAC3 131/4885HDAC1 164/4885
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 STAT6 319/4885HDAC3 3532/4885HDAC1 3946/4885
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 STAT6 319/4885HDAC3 3532/4885HDAC1 3946/4885
US-11414410-B2 Inhibitors of protein kinases MAP3K1, MAP3K20, MAP3K2 STAT6 765/4885HDAC3 700/4885HDAC1 479/4885
US-20140031361-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 STAT6 319/4885HDAC3 3532/4885HDAC1 3946/4885
US-20150094298-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 STAT6 319/4885HDAC3 3532/4885HDAC1 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.